Rein Therapeutics (RNTX) AI Stock Analysis

• Market Cap: $33.93M
• Dividend Yield: N/A
• Average Volume (3M): 228.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: 15.35%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 28,039,032
• 10 Day Avg. Volume: 262,542
• 30 Day Avg. Volume: 228,948
• PEG Ratio: 0.01
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.52
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.39
• 1Y Price Target: $10.00
• Price Target Upside: 693.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▲(19.05% Upside)
• Action: Reiterated Date: 03/27/26
• Date: Action: Reiterated 03/27/26

The score is driven down primarily by weak financial performance (no revenue, sizable losses, and continued cash burn with a shrinking equity base). Technical indicators are broadly neutral with slight near-term improvement, while valuation is constrained by negative earnings and no dividend support. The recent note financing is a modest positive as it can help fund operations.

Positive Factors

Very Low Leverage

Minimal debt reduces fixed financial obligations and lowers default risk, which is important for a clinical-stage biopharma without product revenue. This structural conservatism preserves optionality, making it easier to allocate scarce cash to R&D and to negotiate future financings without heavy interest expense.

Negative Factors

Pre-revenue Profile

With zero reported revenue, the company lacks operational validation and cannot self-fund development from product sales. This structural absence of commercial cash flows prolongs dependence on capital markets, increases dilution risk for shareholders, and leaves the firm vulnerable if fundraising conditions tighten.

Rein Therapeutics Business Overview & Revenue Model

Company Description

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate...

Read more

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate...

How the Company Makes Money

null...

Rein Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Mar 2024	Mar 2023	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.00K	0.00	0.00	0.00	0.00
EBITDA	-21.93M	-28.05M	-15.23K	-27.48K	-26.48K
Net Income	-49.87M	-62.88M	-15.73K	-27.33K	-26.16K
Balance Sheet
Total Assets	24.16M	69.24M	106.01M	22.01M	48.48M
Cash, Cash Equivalents and Short-Term Investments	3.21M	12.87M	17.31M	21.24M	45.93M
Total Debt	0.00	0.00	48.00K	33.00K	162.00K
Total Liabilities	7.24M	14.85M	99.12M	3.38M	4.58M
Stockholders Equity	16.92M	54.39M	6.89M	18.62M	43.90M
Cash Flow
Free Cash Flow	-19.36M	-22.29M	-19.81M	-24.86M	-23.91M
Operating Cash Flow	-19.36M	-22.29M	-19.81M	-24.86M	-23.75M
Investing Cash Flow	0.00	0.00	16.20M	26.46M	-35.92M
Financing Cash Flow	9.76M	17.82M	15.79M	0.00	55.66M

Rein Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.25, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 52.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNTX.

Rein Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OKUR	52 Neutral	$55.65M	-0.66	-115.64%	―	―	46.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KZR	50 Neutral	$54.55M	-0.82	-62.53%	―	―	35.80%
RNTX	47 Neutral	$33.93M	-0.59	-217.16%	―	―	15.35%
RANI	44 Neutral	$99.62M	-3.01	-718.54%	―	―	25.08%
VVOS	43 Neutral	$13.61M	-1.57	-335.47%	―	18.76%	60.09%

Rein Therapeutics Corporate Events